nach oben

Malaria Journal

Erschienen in:

Open Access 01.12.2018 | Research

A systematic review of transfusion-transmitted malaria in non-endemic areas

verfasst von: Federica Verra, Andrea Angheben, Elisa Martello, Giovanni Giorli, Francesca Perandin, Zeno Bisoffi

Erschienen in: Malaria Journal | Ausgabe 1/2018

Abstract

Background

Transfusion-transmitted malaria (TTM) is an accidental Plasmodium infection caused by whole blood or a blood component transfusion from a malaria infected donor to a recipient. Infected blood transfusions directly release malaria parasites in the recipient’s bloodstream triggering the development of high risk complications, and potentially leading to a fatal outcome especially in individuals with no previous exposure to malaria or in immuno-compromised patients. A systematic review was conducted on TTM case reports in non-endemic areas to describe the epidemiological characteristics of blood donors and recipients.

Methods

Relevant articles were retrieved from Pubmed, EMBASE, Scopus, and LILACS. From each selected study the following data were extracted: study area, gender and age of blood donor and recipient, blood component associated with TTM, Plasmodium species, malaria diagnostic method employed, blood donor screening method, incubation period between the infected transfusion and the onset of clinical symptoms in the recipient, time elapsed between the clinical symptoms and the diagnosis of malaria, infection outcome, country of origin of the blood donor and time of the last potential malaria exposure.

Results

Plasmodium species were detected in 100 TTM case reports with a different frequency: 45% Plasmodium falciparum, 30% Plasmodium malariae, 16% Plasmodium vivax, 4% Plasmodium ovale, 2% Plasmodium knowlesi, 1% mixed infection P. falciparum/P. malariae. The majority of fatal outcomes (11/45) was caused by P. falciparum whilst the other fatalities occurred in individuals infected by P. malariae (2/30) and P. ovale (1/4). However, non P. falciparum fatalities were not attributed directly to malaria. The incubation time for all Plasmodium species TTM case reports was longer than what expected in natural infections. This difference was statistically significant for P. malariae (p = 0.006). A longer incubation time in the recipient together with a chronic infection at low parasite density of the donor makes P. malariae a subtle but not negligible risk for blood safety aside from P. falciparum.

Conclusions

TTM risk needs to be taken into account in order to enhance the safety of the blood supply chain from donors to recipients by means of appropriate diagnostic tools.

Federica Verra and Andrea Angheben contributed equally to this work

confidence interval

ELISA

enzyme-linked immunosorbent assay

EMBASE

Excerpta Medica dataBASE

FFP

fresh frozen plasma

IFAT

indirect immunofluorescent antibody test

LILACS

Latin America and the Caribbean Health Sciences Literature

light microscopy

MeSH

medical subject heading

MMWR

morbidity and mortality weekly report

MTM

mosquito transmitted malaria

PCR

polymerase chain reaction

PLT

platelet

RBC

red blood cell

TTM

transfusion transmitted malaria

USA

United States of America

whole blood

WHO

World Health Organization

Background

Malaria is an infectious disease caused by intracellular protozoan parasites of the genus Plasmodium responsible for a potentially fatal acute febrile illness following invasion and multiplication in human red blood cells (RBCs) during their complex life cycle. Five species of Plasmodium are currently known to cause malaria in humans: the deadliest Plasmodium falciparum and Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Plasmodium knowlesi. Malaria parasites are naturally transmitted by the infective bites of female Anopheles mosquitoes during their blood meal. Malaria can manifest with severe symptoms leading to a fatal outcome in non-immune individuals, often young children and pregnant women in endemic areas or naïve adults in non-endemic settings, and remains asymptomatic in adults who have acquired a premunition maintained by repeated antigen exposure.

Transfusion-transmitted malaria (TTM) is an accidental Plasmodium infection caused by the transfusion of whole blood or a blood component from a malaria infected donor to a recipient, described for the first time by Woolsey in 1911 [1], that may cause severe clinical symptoms in the recipients, especially in those with no previous exposure to malaria or in immuno-compromised patients due to other coexisting diseases. Several systematic reviews have addressed the knowledge gap still existing in the epidemiology of TTM in the United States [2], Canada [3] and the Americas [4].

Plasmodium falciparum, P. vivax and P. malariae are the species most frequently detected in TTM [5]. Various aspects of the parasite biology make this accidental route of infection feasible such as the persistence of infection: P. falciparum can persist for at least 1 year before being cleared, P. vivax for 3 years whereas P. malariae is known to remain as a chronic infection at low density for decades [6]. All Plasmodium species are able to survive in stored blood, even if frozen, and retain their viability for at least 1 week, possibly well over 10 days depending on the conditions of storage; in fact, microscopically detectable malaria parasites were present even after 28 days of storage at 4 °C although a decrease of infectivity after 2 weeks was observed [6, 7]. An important difference between the natural infection and TTM is that the former undergoes an initial asymptomatic phase (pre-erythrocytic) which allows the activation of innate immunity cells against malaria parasites. This early phase has advantages on both sides of the host parasite arms race: the innate immunity gives the naïve host time to develop a more specific protective immunity; meanwhile the parasites manipulate the host’s immune system in order to escape. Infected blood transfusions directly release malaria parasites in the recipient’s bloodstream triggering the development of high risk complications and potentially leading to a fatal outcome [8]. Experimental evidence suggests that as few as 10 infected RBCs can be sufficient to transmit the infection; thus, even a small inoculum is potentially infectious. However, the mean incubation period for TTM is generally longer than the mean incubation period for the mosquito-transmitted malaria (MTM) for all Plasmodium species as reported by [9]: 16.0 (8–29) days for P. falciparum TTM compared to 13.1 (7–27) days in P. falciparum MTM; 57. 2 (6–106) days for P. malariae TTM compared to 34.8 (27–37) days for P. malariae MTM; 19.6 (8–30) days for P. vivax TTM compared to 13.4 (8–31) days for P. vivax MTM; 23 days for P. ovale TTM compared to 13.6 (11–16) days for P. ovale MTM [9]. Blood components such as RBCs, platelets and plasma, are commonly transfused to treat various conditions ranging from surgical procedures causing a temporary anaemia to a chronic one due to haematological disorders (haemoglobinopathies, glucose-6-phosphate-dehydrogenase (G6PD) deficiency, haemophilia). Blood banks require a preliminary screening of a potential blood donor to exclude the risk of current or previous infections which can be transmitted by a blood transfusion, including malaria. Criteria for haemovigilance are defined by the World Health Organization (WHO) and are adapted to each country according to national guidelines. Some countries such as USA rely on a pre-donation questionnaire for the screening of potential infected donors whereas some others, including France, UK and Australia, use antibody testing on donors who are considered at risk on the basis of the preliminary questionnaire [3]. Appropriate diagnostic tools need to be employed in order to enhance the safety of the blood supply chain from donors to recipients tailored to the local TTM risk. The sensitivity and specificity of the screening strategy of blood donors remains the crucial issue in order to ensure the safety of blood transfusions particularly in the case of malaria: in fact, serological tests currently employed do not indicate the actual parasitaemia because antibody levels can remain elevated for many years after infection of P. falciparum and P. vivax [10]. Also, the initial clinical symptoms are generally aspecific making the diagnosis more difficult and resulting in a further delay. Delayed or missed diagnosis of P. falciparum in particular increases the risk of severe disease which may be fatal especially in non-immune individuals.

Furthermore new technologies are available to selectively inactivate pathogens without damaging cells or plasma; a combination of riboflavin as a photosensitizer with a UV light illumination device (Mirasol System for Whole Blood; Terumo BCT, Lakewood, Colo.) proved to substantially reduce P. falciparum infectivity in whole blood samples without altering cell quality parameters [11]; this inactivation technology may well represent another layer of control to reduce the risk of TTM.

Lastly, infected recipients who do not develop any clinical illness may become asymptomatic carriers and thus a reservoir of malaria parasites if competent vectors were to be present; this event has serious implications especially in non-endemic countries where the majority of the population has never been exposed to malaria parasites.

The primary objective of this systematic review was to describe the epidemiological characteristics of TTM in non-endemic countries based on data available in the literature in order to evaluate the extent and dynamics of this particular risk of malaria transmission. The review specifically investigated: (i) which Plasmodium species are more often detected in TTM; (ii) if other Plasmodium species besides P. falciparum are likely to cause a lethal outcome of TTM; (iii) whether the incubation time in TTM is longer than in the natural infection; (iv) which blood component is more likely to be infective for the recipient (whole blood, red blood cells, platelets or plasma); (v) which diagnostic methods were used in donor screening and recipient diagnosis (microscopy, serological or molecular tests).

Methods

Literature search

A systematic review of all articles on TTM in non-endemic areas was carried out. Relevant articles were retrieved from Pubmed, EMBASE, Scopus, and LILACS databases using combinations of the following search terms: “malaria”, “blood transfusion”, “Plasmodium”, “transfusion”, adapted to each database without date or language restrictions until May 17th 2017. TTM cases in USA were retrieved from the annual Morbidity and Mortality Weekly Reports (MMWR) malaria surveillance reports. The following combination of MeSH and free string terms were used specifically in Pubmed:

((“Platelet Transfusion”[MeSH] OR “Transfusion Medicine”[MeSH] OR “Lymphocyte Transfusion”[MeSH] OR “Leukocyte Transfusion”[MeSH] OR “Erythrocyte Transfusion”[MeSH] OR “Blood Component Transfusion”[MeSH]) OR (Transfusion*)) AND ((malaria*) OR (Plasmodi*) OR (malaria [MeSH])). Original research papers were included and additional references retrieved from narrative reviews; restriction to case reports was deemed necessary as the main scope of this systematic review was to investigate in fine details the relevant characteristics of each reported case of TTM. Two independent investigators (FV, EM) screened titles and abstracts, selected articles for full text review, performed the final article selection; a third reviewer (AA) was consulted in case of disagreement in order to reach a consensus. Case reports were excluded if the Plasmodium species was described as “tertian” without further identification. Also, case reports occurred in malaria endemic countries were not considered unless the case report was ascertained to have happened in a non-endemic area of the country. Articles in Chinese, Russian, Arabic and Turkish languages without at least a summary in English were dropped. From each study the following data was extracted: study area, gender and age of blood donor and recipient, blood component transfused, Plasmodium species, malaria diagnostic method employed, blood donor screening method, incubation period (i.e. the time elapsed between the infected transfusion and the onset of clinical symptoms in the recipient), delayed diagnosis (i.e. time elapsed between the onset of clinical symptoms and the diagnosis of malaria), infection outcome, country of origin of the blood donor and time of the last potential malaria exposure. The protocol for this systematic review was published on PROSPERO database with the registration number CRD 42017062298.

Statistical analysis

The incubation time of each TTM case report was analysed through standard one sample two-tailed t-tests (level of significance α = 0.05) to evaluate the difference between incubation periods of TTM and MTM for each Plasmodium species. Reference mean values of MTM were drawn from the results shown by Dover and Schultz [9]. All statistical analyses were performed using R software, version 3.3.3 [12].

Results

The number of selected papers at each step of the screening and criteria for exclusion/inclusion are reported in the flow diagram (Fig. 1); 100 case reports of TTM were retrieved for the purpose of this review and the main epidemiological data is provided by Table 1. Fifty-four of these case reports occurred in the American continent, 38 in Europe, 3 in the Mediterranean area, 1 in India, 4 in South-East Asia.

Table 1

Reported cases of transfusion- transmitted malaria (TTM) in malaria non-endemic areas

Country^a	Year	Donor gender and age	Donor origin and last exposure	Recipient gender and age	Recipient incubation (delayed diagnosis)	Recipient outcome	Blood component transfused	Plasmodium species	Diagnosis method recipient (donor)	References
Canada
Western region	1936	M	Mediterranean area	F 13 years	3 weeks (5 weeks)	Recovery	WB	P. malariae	LM (LM)	[17]
Ontario	1936	M	Romania 25 years	F	26 days (2 weeks)	Recovery	WB	P. malariae	LM (LM)	[18]
Alberta	1977	F 23 years	Africa 2 years	F 60 years	29 days (29 days)	Recovery	WB	P. ovale	LM (IFAT)	[19]
Quebec	1994	N/A	Cameroon > 3 years	M 63 years	N/A (3 weeks)	Recovery	RBCs, PLTs, FFP	P. falciparum	LM (LM)	[20]
Ontario	1995	M	Mali 4 years	F 24 years	15 days (3 days)	Recovery	RBCs	P. falciparum	LM, PCR (PCR)	[20]
Ontario	1997	F 19 years	Ghana 4 years	F 62 years	21 days (5 weeks)	Recovery	RBCs, FFP	P. falciparum	LM, PCR	[20]
USA
New York	1911	N/A	N/A	M 54 years	11 days	“Pernicious anaemia”	WB	P. vivax	LM	[1]
Colorado	1929	M 32 years	Greece 16 years	F 2½ years	19–25 days (on the day)	Recovery	WB	P. malariae	LM (LM)	[21]
New York	1932	M	Italy	F 1.5 years	4 weeks (17 days)	Recovery	WB	P. malariae	LM	[22]
New York	1932	M	Italy 12 years	M 9 months	6 weeks	Recovery	WB	P. malariae	LM	[22]
New York	1933	F	Greece	F 8 years	< 8 weeks	Death due to pneumonia	WB	P. malariae	LM	[22]
New York	1936	M	Greece 33 years	F 1 year	29 days	Recovery	WB	P. malariae	LM	[22]
New York	1936	M	Colombia 10 years	M 3 years	2 months	Recovery	WB	P. malariae	LM	[22]
New York	1944	M 40 years	North Africa veteran 1 year	F 32 years	11–4 days (35 days)	Recovery	WB	P. malariae	LM (LM)	[23]
Rhode Island	1946	M or F	Italy or New England	F 40 years	2 months (2 days)	Recovery	WB, FFP	P. malariae	LM (LM)	[24]
Pennsylvania	1946	N/A	Army returnee	F	3 weeks (9 days)	Recovery	WB	P. vivax	LM	[25]
California	1968	M 19 years	Vietnam veteran 7 months	M 60 years	4 days (on the day)	N/A	WB	P. falciparum	LM (LM)	[26]
Connecticut	1968	N/A	Mexico 5 years	F 8 months	6 ½ months	Recovery	WB	P. malariae	LM	[27]
Washington state	1968	M 22 years	Vietnam veteran 1 year	F 54 years	13 days (9 days)	Recovery	WB	P. falciparum	LM (LM, IFAT)	[28]
Oklahoma	1968	M 21 years	Vietnam veteran 5 months	F 25 years	16 days (7 days)	Recovery	WB	P. falciparum	LM (LM)	[28]
Washington D.C.	1969	M	Nigeria > 2 years	M 56 years	17 days (6 days)	Death	WB	P. falciparum	LM (LM, IFAT)	[29]
New York	1970	M	Ghana 1 year	M 34 years	6 days (2 days)	Recovery	WB	P. falciparum	LM (LM, IFAT)	[30]
Chicago	1972	N/A	N/A	M 5 months	16 days (6 days)	Recovery	WB	P. vivax	LM	[31]
New York	1971	N/A	N/A	M 24 years	Multiple transfusions (7 days)	Recovery	WB	P. vivax	LM (IFAT)	[32]
New York	1974	N/A	N/A	F 42 years	9 weeks (on the day)	Recovery	RBCs, PLTs, FFP	P. malariae	LM (IFAT)	[32]
New York	1974	F 53 years	Greece 22 years	F 78 years	Multiple transfusions (~ 30 days)	Recovery	WB, RBCs	P. malariae	LM, IFAT (IFAT)	[33]
New York	1974	M 38 years	Cyprus 4 years	F 42 years	35 days (1 month)	Recovery	RBCs, PLTs, FFP	P. malariae	LM, IFAT (IFAT)	[33]
Tennessee	1974	M 28 years	Nigeria 8 years	F 15 years	3 months (12 days)	Recovery	WB	P. malariae	LM (LM, IFAT)	[34]
Wisconsin	1977	N/A	Africa recent	F 57 years	Multiple transfusions (28 days)	Death due to refractory leukaemia	PLTs	P. falciparum	LM (LM)	[35]
New York state	1978	M	Ghana 10 months	F 65 years	16 days (1 day)	Recovery	WB, RBCs, FFP	P. falciparum	LM (IFAT)	[36]
California	1980	M	N/A	M 6 years	15 days (2 days)	Recovery	RBCs	P. falciparum	LM (LM)	[37]
California	1982	M	Nigeria 7 years	M premature	6 weeks	Death due to pneumonia	WB	P. ovale	LM, IFAT (IFAT)	[38]
Boston	1982	N/A	N/A	M premature	7 weeks (on the day)	Recovery	RBCs	P. malariae	LM (LM)	[39]
Boston	1982	N/A	N/A	M premature	10 weeks (on the day)	Recovery	RBCs	P. malariae	LM (LM)	[39]
California	1983	M	Guatemala 6 months	M premature	5 weeks (on the day)	Recovery	WB	P. vivax	LM (LM)	[40]
California	1983	M	South America 6 months	M infant	14 days (on the day)	Recovery	WB	P. vivax	LM (IFAT)	[40]
Texas	1992	M 19 years	Nigeria 7 months	F 71 years	7 days (on the day)	N/A	RBCs, PLTs	P. falciparum	LM (IFAT)	[41]
Texas	1992	M 19 years	Nigeria 7 months	M 65 years	N/A	N/A	RBCs	P. falciparum	LM (IFAT)	[41]
California	1992	M 55 years	China 44 years	M 44 years	7 months (3 months)	Recovery	RBCs	P. malariae	LM (IFAT)	[41]
Texas	1994	M	Nigeria recent	F 59 years	20 days (on the day)	Recovery	RBCs	P. falciparum	LM (LM, IFAT)	[42]
Texas	1994	M	Ghana recent	M 46 years	16 days (7 days)	Recovery	RBCs, FFP	P. falciparum	LM (LM, IFAT)	[42]
Pennsylvania	1995	M	Nigeria 3 years	F 72 years	Multiple transfusions	Recovery	RBCs	P. falciparum	LM (LM, IFAT)	[43]
Missouri	1996	M	West Africa 1 year	M 70 years	15 days (on the day)	Death	RBCs	P. falciparum	LM (LM, IFAT, PCR)	[44]
Missouri	1997	M	West Africa 2 years	M 85 years	21 days (on the day)	Death	RBCs	P. falciparum	LM (LM, IFAT, PCR)	[44]
Pennsylvania	1998	M	West Africa 2 years	M 49 years	35 days (on the day)	Recovery	RBCs	P. falciparum	LM (IFAT, PCR)	[44]
Texas	2003	M	Ghana 2 years	69 years	17 days (3 days)	Recovery	RBCs	P. falciparum	LM (LM, PCR, IFAT)	[45]
Texas	2007	M	Nigeria 6 years	F 25 years	Multiple transfusions	Recovery	RBCs	P. falciparum	LM (IFAT)	[46]
Washington D.C.	2007	M	West Africa	F	15 days (on the day)	Recovery	RBCs	P. falciparum	LM, PCR (LM)	[47]
Washington D.C.	2007	M 27 years	Nigeria 3 years	M 27 years	13–28 days (11 days)	Recovery	RBCs	P. falciparum	LM (IFAT, PCR)	[47]
New Jersey	2007	F 30 years	Uganda > 1 year	M 78 years	1 year	Recovery	RBCs	P. falciparum	LM (IFAT, PCR)	[47]
N/A	2007	M 21 years	Benin 4 years	F 55 years	1 month	Recovery	RBCs, PLTs, FFP	P. falciparum	LM, IFAT, PCR (IFAT, EIA)	[48]
Georgia	2015	M 20 years	Liberia 15 years	M 76 years	6 months (2 days)	Recovery	RBCs, FFP	P. malariae	LM, PCR (LM, PCR, ELISA)	[49]
Colombia
Cali	2011	N/A	Rural area 9 months	F Premature	Multiple transfusions (on the day)	Recovery	RBCs	P. vivax	LM (PCR)	[50]
Brasil
Sao Paulo	2008	M	Atlantic forest 1 year	N/A	75 days (on the day)	Recovery	RBCs, PLTs, FFP	P. malariae	LM (LM, PCR, IFAT)	[51]
Spain
Valencia	1987	N/A	Congo	F 32years	7 days (on the day)	N/A	WB	P. falciparum	LM (IFAT)	[52]
Madrid	1997	N/A	Central Africa	F 63 years	3 weeks (4 weeks)	N/A	WB	P. falciparum	LM (IFAT)	[53]
Cordoba	2002	N/A	N/A	F 26 years	Multiple transfusions (128 days)	Recovery	WB, RBCs	P. falciparum	LM IFAT	[54]
UK
Midlands	1935	M	India 2 years	M 26 years	19 days (5 days)	Recovery	WB	P. vivax	LM (LM)	[55]
London	1938	M	Ceylon 12 years	F 3 months	10 weeks (on the day)	Death	WB	P. malariae	LM (LM)	[56]
Durham	1946	M	Yemen 7 years	F 18 years	7–8 weeks (10 days)	Recovery	WB	P. malariae	LM (LM)	[57]
N/A	1959	M 19 years	Nigeria 1 year	F 41 years	16 days (6 days)	Recovery	WB	P. falciparum	LM (LM)	[58]
Oxford	1966	M	Far East 20 years	M 33 years	10 weeks (1 day)	Recovery	WB, FFP	P. malariae	LM (LM)	[59]
Buckingmanshire	1967	M	Army returnee	M 51 years	N/A	Recovery	FFP	P. malariae	LM (LM)	[60]
Buckingmanshire	1968	M	Africa 18 months	M 49 years	11 days (12 days)	Recovery	WB	P. falciparum	LM (LM, IFAT)	[60]
London	1986	M	Africa	F 72 years	13 days (12 days)	N/A	PLTs	P. falciparum	LM (LM, IFAT)	[61]
London	1986	M	Ghana	F 81 years	14 days	N/A	WB	P. falciparum	LM (IFAT)	[61]
N/A	1994	F	Ghana 1 year	M	15 days (on the day)	N/A	WB	P. falciparum	LM (EIA, IFAT)	[5]
N/A	1997	F 19 years	Ghana 3 years	M 62 years	4 days	Death	WB	P. falciparum	(EIA, IFAT)	[5]
N/A	2003	F 38 years	Ghana 7 years	M 51 years	N/A	Death	WB	P. falciparum	LM (EIA, IFAT)	[5]
Netherlands
Leiden	2011	M 36 years	Africa Costa Rica > 4 years	F 59 years	2 months (on the day)	Recovery	RBCs	P. malariae	LM, PCR (LM, IFAT, PCR)	[62]
Germany
Göttingen	1998	N/A	N/A	M 18 months	14 days (9 days)	Recovery	RBCs	P. falciparum	LM	[63]
France
Poitiers	1969	M	Portugal 5 months	F	15 days (1 month)	Recovery	WB	P. malariae	LM (IFAT)	[64]
Paris	1957	F	Tunisia 27 years	F 32 years	48 days (4 days)	Recovery	WB	P. vivax	LM	[65]
Paris	1973	M	Senegal 13 years	M 30 years	14 days (9 days)	Recovery	WB	P. falciparum	LM (IFAT)	[65]
Paris	1975	N/A	N/A	F 24 years	15 days (18 days)	Recovery	WB	Plasmodium	LM (IFAT)	[66]
Tours	1977	N/A	N/A	F 47 years	15 days (on the day)	Recovery	WB	P. vivax	LM	[67]
Rouen	1976	N/A	Senegal	N/A	12 days (10 days)	Death	N/A	P. falciparum	(IFAT)	[68]
Rouen	1976	N/A	Ivory Coast	N/A	13 days (6 days)	Death	N/A	P. falciparum	(IFAT)	[68]
Rouen	1978	N/A	N/A	N/A	60 days (2 days)	Recovery	N/A	P. malariae	(IFAT)	[68]
Nancy	1979	M	Zaire 1 month	F 29 years	15 days (43 days)	Recovery	RBCs	P. falciparum P. malariae	LM (IFAT)	[69]
Crèteil	1980	M	Central Africa	M infant	2 months (3 days)	Recovery	RBCs, FFP	P. malariae	LM	[70]
Aulnay-sous-Bois	1986	N/A	N/A	F 64 years	16 days (on the day)	Recovery	WB	P. ovale	LM	[71]
Libourne	1990	M	Comores < 6 months	F 39 years	1 month (on the day)	Recovery	WB	P. falciparum	LM	[72]
Le Chesnay	2002	F 19 years	Africa 4 years	M 81 years	13 days (4 days)	Death	RBCs	P. falciparum	LM, IFAT, PCR (IFAT, PCR)	[73]
Tourcoing	2013	N/A	Endemic area 3 years	F 75 years	14 days (8 days)	Death	RBCs	P. falciparum	LM (IFAT, PCR)	[74]
Switzerland
Zurich	1999	M 30 years	Cameroon 6 years	M 70 years	14 days (22 days)	Death	RBCs, FFP	P. falciparum	LM (IFAT, PCR)	[75]
Austria
Wien	1929	M	Endemic area 10 years	N/A	14 days	Recovery	WB	P. vivax	LM	[76]
Italy
Liguria	1963	N/A	N/A	M Premature	28–40 days	Recovery	WB	P. malariae	LM	[77]
Liguria	1963	N/A	N/A	F 8 years	1–13 days	Recovery	WB	P. vivax	LM	[78]
Liguria	1964	N/A	N/A	F 6 years	Multiple transfusions (4 months)	Recovery	WB	P. vivax	LM	[78]
Sicily	2005	M	Philippine	F 35 years	Multiple transfusions (4 months)	Recovery	WB	P. malariae	LM	[79]
Veneto	2008	N/A	N/A	F 29 years Morocco	Multiple transfusions (2 weeks)	Recovery	RBCs	P. vivax	LM	[80]
Algeria
Algiers	1918	M	Greece 1 month	F	15 days (few days)	Recovery	WB	P. praecox ^b	LM (LM)	[13]
Lebanon
Beirut	2007	N/A	N/A	M 28 years	1 ½ months (2 weeks)	Recovery	RBCs	P. falciparum	LM	[81]
Beirut	2010	N/A	N/A	F 46 years	1 month (2 days)	Recovery	RBCs	P. ovale	LM	[82]
India
Shimla	2006	N/A	N/A	F 47 years	12 days (on the day)	Recovery	WB	P. falciparum	LM	[83]
Korea
Taegu, South Corea	2000	M 21 years	Endemic area	M 1 year	15 days (5 days)	Recovery	RBCs, FFP	P. vivax	LM (LM, PCR)	[84]
Thailand
Bangkok	2011	M teenager	Endemic area 3 weeks	F 62 years	15 days (on the day)	Recovery	RBCs	P. knowlesi	LM, PCR	[85]
Malaysia
Kuala Lumpur	2012	M 26 years	Myanmar 9 months	M 12 years	1 week (on the day)	N/A	WB	P. vivax	LM, PCR (PCR)	[86]
Sabah	2015	M 51 years	Endemic area	F 23 years	16 days (on the day)	Recovery	WB	P. knowlesi	LM, PCR (LM, PCR)	[87]

N/A data not available, WB whole blood, RBCs red blood cells, PLTs platelets, FFP fresh frozen plasma, LM light microscopy, ELISA enzyme-linked immunosorbent assay, IFAT indirect immunofluorescent antibody test, PCR polymerase chain reaction

^aOnly non-endemic areas of the country if malaria endemic were included

^bPossible misidentification of P. falciparum

The first report of TTM went back to 1911 and the most recent occurred in 2015, both in USA. The age of TTM case reports ranged from premature children to an 85 years old individual. The partitioning of cases in children and adults (≥ 18 years) when age was available resulted in 2 children and 39 adults for P. falciparum, 14 children and 12 adults for P. malariae, 8 children and 6 adults for P. vivax, 1 child and 3 adults for P. ovale, and 2 adults for P. knowlesi. Female versus male ratio was 1:1 for recipients and 1:6 for donors.

Plasmodium species. The most common Plasmodium species detected in TTM resulted to be P. falciparum (45%) and P. malariae (30%); P. vivax, P. ovale were less frequently observed: 16 and 4% respectively; two TTM were caused by P. knowlesi (2%), and one by a mixed infection P. falciparum/P. malariae. Plasmodium praecox, an avian Plasmodium species, was described in a case report whose infection was acquired in Greece [13].

ii.

Species involved in fatal outcomes. The majority of fatal outcomes (11/45) was indeed caused by P. falciparum whilst all the other fatalities occurred in individuals infected by P. malariae (2/30) and P. ovale (1/4).

iii.

Incubation period (IP). Table 2 shows the differences in the mean incubation times for each Plasmodium species between TTM and MTM. For all species, the mean incubation time in TTM was longer, but the most relevant difference was observed for P. malariae (63.9 vs 34.6 days, p = 0.006).

Table 2

Mean values of transfusion-transmitted malaria (TTM) versus mosquito-transmitted malaria (MTM) incubation time in days

Species	TTM (95% CI)	MTM (95% CI)^a	p value^b
P. falciparum	25.7 (7.4–43.9)	13.1 (7–27)	0.172
P. malariae	63.9 (43.5–84.4)	34.8 (27–37)	0.006
P. ovale	19.0 (11.7–26.3)	13.6 (8–31)	0.118
P. vivax	29.3 (12.3–46.2)	13.4 (11–16)	0.060
P. knowlesi ^c	15.5 (9.1–21.9)	10.0 (/)	0.058

CI confidence interval

Significance threshold p value <0.05 (in italic)

^aAs reported by Dover and Schultz [9]

^bObtained through one sample two-tailed Student’s t test, using the MTM mean value for the null hypothesis

^cA range of the mean incubation time for this species in humans was not available in literature, so a direct comparison of CIs was not possible

iv.

Blood component causing TTM. The vast majority of TTM cases were caused by whole blood and/or RBCs transfusion; however, two TTM cases due to platelets and one TTM case due to plasma only were reported.

Diagnostic method used for screening (if any) and diagnosis. They are also reported in detail in Table 1. Classical Light microscopy (LM) was the diagnostic method used in virtually all cases of TTM. Only in very few cases this was complemented by serology (IFAT: first time in 1974 for a case of P. malariae occurred in US, ex-Cyprus) and/or PCR (first time in 1995 for a case of P. falciparum occurred in Canada, ex-Mali). Donor “screening” was in fact in the earlier cases the diagnosis subsequently made on the donor, classically with microscopy. Serology (IFAT) was first reported on donors in 1968 (a case of P. falciparum occurred in UK, ex-Africa, and a case of the same species occurred in US, ex-Vietnam). When reported, serology (most often IFAT) appears to be by and large the most frequent method used for donor screening.

Discussion

Transfusion-transmitted malaria is an alternative accidental Plasmodium infection which may cause morbidity and mortality especially in non-endemic areas where individuals have no premunition to malaria. Given the long-time span, over a century, of the case reports some countries which were endemic several decades ago are now malaria free such as the case of Greece and Italy. Therefore, it was not possible to infer any particular geographical pattern of TTM, whose occurrence may reflect people movements due to historical events as well as the proximity to a malaria endemic areas; an example is provided by the numerous army returnees from Vietnam to USA in the late 1960s who were not identified at the time as potential malaria infected blood donors, and caused an increase of TTM cases in the following years in USA [9]. Also, a limitation of this systematic review was due to the selection of exclusively case reports in order to describe the main characteristics of each episode; thus, prevalence studies were discarded as well as data on the occurrence of “transfusion outbreaks” such as the 54 cases of P. vivax TTM reported by the WHO to have taken place in Spain in 1971 due to a single blood bank in Barcelona [14]. Further limitations are due to the intrinsic nature of a systematic review based on different reports hampering the possibility to ascertain retrospectively how reliable were the clinical history and the timing of the diagnosis for each TTM case. The majority of fatal outcomes (11/45) was indeed caused by P. falciparum whilst all the other fatalities occurred in individuals infected by P. malariae (2/30) and P. ovale (1/4). However, these other fatalities were not attributable to malaria: two deaths were due to pneumonia and one was due to the complications of a premature newborn. Furthermore, all fatalities caused by P. falciparum were observed in adults and elderly people, which may reflect other co-morbidities or a more severe prognosis of malaria in adults compared to children within non-immune populations [15].

There are important differences between malaria natural infection and TTM with respect to the incubation time and delayed diagnosis: a longer incubation period was observed for all Plasmodium species as reported by Dover and Schultz [9] despite the absence of the pre-erythrocytic phase as the infected blood component directly transmits the erythrocytic stage of the parasite, namely the merozoite, to the recipient. This paradoxical phenomenon might be explained by the small inoculum of parasites from an asymptomatic donor which requires a longer period of time to develop the clinical symptoms [6]. The incubation period of TTM case reports was confirmed to be longer than the one described in natural infections as shown in Table 2: the difference reached statistical significance (p = 0.006) in P. malariae, which is arguably the species with the longest incubation time and lowest parasite density. No other statistically significant difference was observed possibly due to the limited number of case reports, thus any interpretation must be taken with caution. Moreover, particularly in some cases of P. falciparum, the IP was surprisingly and unusually long, and, although it might explained in theory by an exceedingly small number of parasites inoculated, a reporting error cannot be excluded. Nevertheless, such potential error is expected to have occurred across all TTM cases, thus making the observation still useful to reinforce the need to extend the window of time for a malaria diagnosis in blood transfusion recipients beyond the expected IP. Moreover, according to the reported data none of the TTM cases occurred in individuals with previous history of malaria, thus ruling out the possibility of recrudescence, circulating anti-malarial antibodies (as it would be the case in malaria endemic areas), or prophylaxis which might have delayed the onset of symptoms and diagnosis. Interestingly, the incubation time of the only mixed P. falciparum and P. malariae infection was of 15 days, a nearly typical incubation time for the dominant P. falciparum species compared to the milder P. malariae which employs 35 days on average to clinically develop.

Furthermore, the observation that almost half of the TTM cases reported in this systematic review are due to P. malariae (N = 30) and P. vivax (N = 16) reinforces the need to consider these other Plasmodium species as a not negligible cause of transfusion-transmitted malaria aside from P. falciparum.

Several layers of complexity underline the risk of TTM in non-endemic areas: on one hand, the limited proportion of potentially infective donors imposes a cost-effective strategy of blood donors screening, on the other hand the accuracy of such screening needs to be optimal for the serious outcomes of TTM in malaria naïve recipients.

In most non-endemic countries the first step in the blood supply chain is an epidemiological questionnaire to assess the potential donor’s risk to be infective which may result in a deferral for two groups of individuals: (i) those who were born and had lived for several years in malaria-endemic areas and (ii) those who were born and are resident in non-endemic areas but had visited an endemic area. According to the European guidelines individuals are acceptable as blood donors when an immunologic or molecular test for malaria is negative after at least 6 months since their last visit to an endemic area. When these donors have resided for more than 3 months in the endemic area, the deferral time may be longer. However long the deferral does not totally exclude infectious semi-immune individuals: in fact cases of TTM have been linked to donations given more than 5 years after the last potential exposure of the donor to P. falciparum and several decades in the case of P. malariae [3].

Conclusions

The Plasmodium species most commonly involved in TTM were, expectedly, P. falciparum and P. malariae, but cases of P. vivax were not infrequent, either. This parasite is not known to remain so long in blood as the two other species, while it shares with P. ovale the phenomenon of hepatic hypnozoites (that, however, are not a possible source of transmission before they reach again the bloodstream).

ii.

Species involved in fatal outcomes. All fatal outcomes attributable to malaria were caused by P. falciparum and none by P. vivax, a parasite that has long been considered benign, although its potential to cause severe malaria has been repeatedly demonstrated in recent years [16].

iii.

The incubation period was longer than the average IP for mosquito-transmitted malaria, which may be a further reason for lack of suspicion and diagnostic delay.

iv.

Almost all TTM cases were caused by whole blood and/or RBCs transfusion, as expected, but for two cases by platelets and one by plasma only.

Classical Light microscopy (LM) was used in all cases of TTM for diagnostic purposes. Only in very few cases this was complemented by serology and/or PCR in the more recent period. Serology (IFAT) was the most frequently used method for donor screening.

WHO regulations on blood donation needs to be reinforced as many of the TTM case reports observed even in the time span since blood safety guidelines were implemented could have been prevented if those guidelines had been applied with stringency. Thus, different strategies need to be combined in order to ensure the safety of blood transfusions i.e. blood donor screening by appropriate diagnostic tools, which should probably include molecular tests, and possibly parasite inactivation of the blood supply.

Authors’ contributions

FV and AA conceived the systematic review. FV and ZB wrote the manuscript after comments and discussion with AA, EM, GG, FP. GG performed the statistical analysis. EM was the second reviewer who double-checked the articles’ selection and data extraction. All authors read and approved the final manuscript.

Acknowledgements

We wish to thank Dr. Virginio Pietra and three anonymous reviewers for critical comments on the manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Not applicable.

Funding

This research received no specific funding from any agency, commercial or not-for-profit sectors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Woolsey G. Transfusion for pernicious anemia. Trans NY Surg Soci. 1911;132–3.

Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344:1973–8.CrossRefPubMed

O’Brien SF, Delage G, Seed CR, Pillonel J, Fabra CC, Davison K, et al. The epidemiology of imported malaria and transfusion policy in 5 nonendemic countries. Transfus Med Rev. 2015;29:162–71.CrossRefPubMed

Alho RM, Machado KV, Val FF, Fraiji NA, Alexandre MA, Melo GC, et al. Alternative transmission routes in the malaria elimination era: an overview of transfusion-transmitted malaria in the Americas. Malar J. 2017;16:78.CrossRefPubMedPubMedCentral

Kitchen AD, Barbara JA, Hewitt PE. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines. Vox Sang. 2005;89:77–80.CrossRefPubMed

Bruce-Chwatt LJ. Transfusion malaria. Bull World Health Organ. 1974;50:337–46.PubMedPubMedCentral

Chattopadhyay R, Majam VF, Kumar S. Survival of Plasmodium falciparum in human blood during refrigeration. Transfusion. 2001;51:630–5.CrossRef

Garraud O. Mechanisms of transfusion-linked parasite infection. Transfus Clin Biol. 2006;13:290–7.CrossRefPubMed

Dover AS, Schultz MG. Transfusion-induced malaria. Transfusion. 1971;11:353–7.CrossRefPubMed

10.

Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, et al. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010;6:e1000770.CrossRefPubMedPubMedCentral

11.

Owusu-Ofori S, Kusi J, Owusu-Ofori A, Freimanis G, Olver C, Martinez CR, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock. 2015;44(Suppl 1):33–8.CrossRefPubMedPubMedCentral

12.

Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017.

13.

Gubb AS. Accidental transference of the malarial parasite in the course of transfusion. Br Med J. 1919;2:74–5.CrossRefPubMedPubMedCentral

14.

Velasco E, Gomez-Barroso D, Varela C, Diaz O, Cano R. Non-imported malaria in non-endemic countries: a review of cases in Spain. Malar J. 2017;16:260.CrossRefPubMedPubMedCentral

15.

Baird JK, Masbar S, Basri H, Tirtokusumo S, Subianto B, Hoffman SL. Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J Infect Dis. 1998;178:592–5.CrossRefPubMed

16.

Naing C, Whittaker MA, Nyunt Wai V, Mak JW. Is Plasmodium vivax malaria a severe malaria? A systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8:e3071.CrossRefPubMedPubMedCentral

17.

Cadham FT. Transmission of malaria by blood transfusion. Can Med Assoc J. 1936;34:428–30.PubMedPubMedCentral

18.

McCulloch E. Quartan malaria transmitted by transfusion. Can Med Assoc J. 1937;7:26–9.

19.

Sawyer DM, Wadsworth LD. Plasmodium ovale malaria in Canada following transfusion. Can Med Assoc J. 1977;117:923.PubMedPubMedCentral

20.

Slinger R, Giulivi A, Bodie-Collins M, Hindieh F, John RS, Sher G, et al. Transfusion-transmitted malaria in Canada. CMAJ. 2001;164:377–9.PubMedPubMedCentral

21.

Stein HB. Transmission of malaria by transfusion. Am J Dis Child. 1932;44:1048–54.CrossRef

22.

Wright FH. Accidental transmission of malaria through the injection of whole blood. J Pediatr. 1938;12:327–49.CrossRef

23.

Sharnoff JG, Geiger J, Selzer I. Malaria transmitted by bank blood transfusion; report of two cases. Am J Clin Pathol. 1945;15:494.CrossRefPubMed

24.

Fischer WJ Jr, York CL. Quartan malaria occurring subsequent to a blood transfusion. N Engl J Med. 1946;235:411–3.CrossRefPubMed

25.

Schrack WD. Malaria infection acquired through blood transfusion. Public Health Rep. 1946;61:1630.PubMed

26.

Chojnacki RE, Brazinsky JH, Barrett O Jr. Transfusion-introduced falciparum malaria. N Engl J Med. 1968;279:984–5.CrossRefPubMed

27.

Czapek EE, Barry DW, Gryboski JD. Malaria in an infant transmitted by transfusion. JAMA. 1968;204:549–50.CrossRefPubMed

28.

Fisher GU, Schultz MG. Unusual host-parasite relationship in blood-donors responsible for transfusion-induced falciparum malaria. Lancet. 1969;2:716–8.CrossRefPubMed

29.

Brooks MH, Barry KG. Fatal transfusion malaria. Blood. 1969;34:806–10.PubMed

30.

Seligman SJ, Choa MS. Transfusion-induced falciparum malaria. JAMA. 1971;217:479.CrossRefPubMed

31.

Seeler RA, Miller RA, Lin CH, Lin SK. Transfusion-induced malaria. Plasmodium vivax in a 5-month-old child. Am J Dis Child. 1973;125:132–3.CrossRefPubMed

32.

Tapper ML, Armstrong D. Malaria complicating neoplastic disease. Arch Intern Med. 1976;136:807–10.CrossRefPubMed

33.

Maulitz RM, Marr JS, Shookhoff HB. Transfusion malaria as a consequence of the 1974 war between Turkey and Greece—two cases. Am J Trop Med Hyg. 1976;25:1–4.CrossRefPubMed

34.

Najem GRSJ. Transfusion-induced malaria from an asymptomatic carrier. Transfusion. 1976;16:473–6.CrossRefPubMed

35.

Garfield MD, Ershler WB, Maki DG. Malaria transmission by platelet concentrate transfusion. JAMA. 1978;240:2285–6.CrossRefPubMed

36.

Yarrish RL, Janas JAS, Nosanchuk JS. Transfusion malaria. Treatment with exchange transfusion after delayed diagnosis. Arch Int Med. 1982;142:187–8.CrossRef

37.

Joishy SK, Lopez CG. Transfusion-induced malaria in a splenectomized β-thalassemia major patient and review of blood donor screening methods. Am J Hematol. 1980;8:221–9.CrossRef

38.

Rawlings JS, Beall SC. Transfusion malaria in a premature infant. Clin Pediatr. 1982;21:638–9.CrossRef

39.

Piccoli DA, Perlman S, Ephros M. Transfusion-acquired Plasmodium malariae infection in two premature infants. Pediatrics. 1983;72:560–2.PubMed

40.

Shulman IA, Saxena S, Nelson JM, Furmanski M. Neonatal exchange transfusions complicated by transfusion-induced malaria. Pediatrics. 1984;73:330–2.PubMed

41.

Transfusion malaria. MMWR. 1992;44.

42.

Transfusion malaria. MMWR. 1994;46.

43.

Transfusion malaria. MMWR. 1995;47.

44.

Transfusion-transmitted malaria—Missouri and Pennsylvania, 1996–1998. MMWR. 1999;48:253–6.

45.

Probable transfusion-transmitted malaria—Houston, Texas, 2003. MMWR. 2003;52:1075–6.

46.

Transfusion malaria. MMWR. 2007;56.

47.

Transfusion malaria. MMWR. 2009;58.

48.

Gonzalez A, Nicolas JM, Munoz J, Castro P, Mas J, Valls ME, et al. Severe imported malaria in adults: retrospective study of 20 cases. Am J Trop Med Hyg. 2009;81:595–9.CrossRefPubMed

49.

Holtzclaw A, Mrsic Z, Managbanag J, Calvano T, Colombo C. Transfusion-transmitted malaria not preventable by current blood donor screening guidelines: a case report. Transfusion. 2016;56:2221–4.CrossRefPubMed

50.

Echeverri D, Barreto DK, Osorio L, Cortés A, Martínez E. A case report of transfusion-transmitted Plasmodium vivax malaria from an asymptomatic donor to a premature newborn. Biomedica. 2012;32:8–12.CrossRefPubMed

51.

Scuracchio P, Vieira SD, Dourado DA, Bueno LM, Colella R, Ramos-Sanchez EM, et al. Transfusion-transmitted malaria: case report of asymptomatic donor harboring Plasmodium malariae. Rev Inst Med Trop São Paulo. 2011;53:55–9.CrossRefPubMed

52.

Notification de un caso de paludismo por transfusion. Boletin Epidemiologico Semanal. 1987.

53.

Pizarro Portillo A, García Polo I, Fernández Dorado MT, Delgado Meliá T. Transfusion induced malaria. Revista Clínica Española. 1998;198:559–60.PubMed

54.

Tejero R, Gallego C, Lacasa MJ, Muñoz J. Nosocomial fever of unknown origin in a patient with polytrauma. Enferm Infecc Microbiol Clin. 2003;21:511–2 (in Spanish).CrossRefPubMed

55.

Thomas WL, Keys S. Accidental transmission of malaria by blood transfusion. Lancet. 1936;227:536–7.CrossRef

56.

Nabarro D, Edward DG. Accidental transmission of malaria. Lancet. 1939;234:556–7.CrossRef

57.

Rogers KB. Quartan malaria transmitted by blood-transfusion; report of a case. Lancet. 1947;2:688.CrossRefPubMed

58.

Grant DB, Perinpanayagam MS, Shute PG, Zeitlin RA. A case of malignant tertian (Plasmodium falciparum) malaria after blood-transfusion. Lancet. 1960;2:469–70.CrossRefPubMed

59.

Vartan AE. Transfusion malaria in a man with Christmas disease. Br Med J. 1967;4:466.CrossRefPubMedPubMedCentral

60.

Dike AE. Two cases of transfusion malaria. Lancet. 1970;1:72–3.CrossRefPubMed

61.

DeSilva MCM, Barbara J. Two cases of transfusion-transmitted malaria (TTM) in the UK. Transfusion. 1988;28:86.

62.

Brouwer EE, van Hellemond JJ, van Genderen PJJ, Slot E, van Lieshout L, Visser LG, Wismans PJ. A case report of transfusion-transmitted Plasmodium malariae from an asymptomatic non-immune traveller. Malar J. 2013;12:439.CrossRefPubMedPubMedCentral

63.

Witt O, Iglauer A, Riggert J, Bommer W, Eber S. Transfusionsmalaria als Ursache von unklarem postoperativen Fieber. Monatsschr Kinderheilkd. 1998;146:1054–6.CrossRef

64.

Payard J, Payard JM, de la Roy YDR, Giraud JR. Le paludisme transfusionnel. A propos d’un cas récent. Revue Francaise de Transfusion. 1970;13:181–7.CrossRefPubMed

65.

Besson P, Robert JF, Reviron J, Richard-Lenoble D, Gentilini M. A propos de deux observations de paludisme transfusionnel. essai de prevention associant un test d’immunofluorescence indirecte aux criteres de selection clinique. Rev Fr Transfus Immunohematol. 1976;19:369–73.CrossRefPubMed

66.

Andrianjafy M, Thuillier M, Gandrille MC. Case report. Presumption of transfusion malaria. Rev Fr Transfus Immunohematol. 1976;19:603–4 (in French).CrossRefPubMed

67.

Choutet P, Guilmot JL, Duong TH, Ginies G, Ravez G, Barrabes A, et al. Transfusional malaria. Another case. Semaine des Hopitaux. 1979;55:1539–41.PubMed

68.

Brasseur P, Bonneau JC. Le paludisme transfusionnel: risque, prévention et coût. Expérience d’une année. Rev Fr Transfus Immunohematol. 1981;24:597–608.CrossRefPubMed

69.

Aymard JP, Vinet E, Lederlin P, Witz F, Colomb JN, Herbeuval R. Post-transfusional malaria: a case of double infection with Plasmodium falciparum and Plasmodium malariae. Rev Fr Transfus Immunohematol. 1980;23:491–3 (in French).CrossRefPubMed

70.

Richaud J, Canet J, Janaud JC. Paludisme post-transfusionnel chez un nourrisson de deux Mois. Archives Francaises de Pediatrie. 1982;39:161–3.PubMed

71.

Giacomini T, Baledent F, Hanania G. Transfusion malaria caused by Plasmodium ovale. A case. Presse Med. 1988;17:755–6.PubMed

72.

Nivet P, Capbern M. A case of transfusional Plasmodium falciparum malaria. Presse Med. 1991;20:1567 (in French).PubMed

73.

Bruneel F, Thellier M, Eloy O, Mazier D, Boulard G, Danis M, et al. Transfusion-transmitted malaria. Intensive Care Med. 2004;30:1851–2.CrossRefPubMed

74.

Joseph C, Meybeck A, Melliez H, Boyer T, Fortin-Lebraud L, Lovi V, et al. Tropical infection after a case of total hip arthroplasty. J Hosp Infect. 2014;87:179–81.CrossRefPubMed

75.

Frey-Wettstein M, Maier A, Markwalder K, Munch U. A case of transfusion transmitted malaria in Switzerland. Swiss Med Wkly. 2001;131:320.PubMed

76.

Flaum E. Wien Klin Wochenschr. 1929;42:589.

77.

Sansone G, Centa A. Malaria caused by transfusion. I. Case in an infant. Pathologica. 1967;59:13–7.PubMed

78.

Sansone G, Centa A. Malaria caused by transfusion. II. Observations on 2 cases in patients splenectomized for Cooley’s disease. Pathologica. 1967;59:119–22.PubMed

79.

Neri SPD, Patamia I, Zoccolo A, Castellino P. Acute renal failure in Plasmodium malariae infection. J Med. 2008;66:166–8.

80.

Tagariello G, Sartori R, Inojosa WO, Candiotto L, Radossi P, Scarpa E, et al. Dramatic post-splenectomy onset of malaria caused by latent Plasmodium vivax in a female immigrant with severe immunological anaemia. Blood Transfus. 2014;12:428–30.PubMedPubMedCentral

81.

Maalouf N, Naja M, El Kinge AR, Zein-El-Dine S, Taher A. Transfusion-transmitted malaria: how vital is the need to screen in non-endemic countries? Transfus Med. 2007;17:415–6.CrossRefPubMed

82.

Haydoura S, Mazboudi O, Charafeddine K, Bouakl I, Baban TA, Taher AT, et al. Transfusion-related Plasmodium ovale malaria complicated by acute respiratory distress syndrome (ARDS) in a non-endemic country. Parasitol Int. 2011;60:114–6.CrossRefPubMed

83.

Chauhan V, Negi RC, Verma B, Thakur S. Transfusion transmitted malaria in a non-endemic area. J Assoc Physicians India. 2009;57:654–6.PubMed

84.

Lee YH, Lee HK, Choi KH, Hah JO, Lim SY. Transfusion-induced malaria in a child after open heart surgery in Korea. J Korean Med Sci. 2001;16:789–91.CrossRefPubMedPubMedCentral

85.

Traipattanakul J, Changpradub D, Trakulhun K, Phiboonbanakit D, Mungthin M. A first case of Plasmodium knowlesi malaria in Phramongkutklao Hospital. J Infect Dis Antimicrob Agents. 2014;31:91–100.

86.

Anthony CN, Lau YL, Sum JS, Fong MY, Ariffin H, Zaw WL, et al. Malaysian child infected with Plasmodium vivax via blood transfusion: a case report. Malar J. 2013;12:308.CrossRefPubMedPubMedCentral

87.

Bird EM, Parameswaran U, William T, Khoo TM, Grigg MJ, Aziz A, et al. Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report. Malar J. 2016;15:357.CrossRefPubMedPubMedCentral

Titel: A systematic review of transfusion-transmitted malaria in non-endemic areas
verfasst von: Federica Verra
Andrea Angheben
Elisa Martello
Giovanni Giorli
Francesca Perandin
Zeno Bisoffi
Publikationsdatum: 01.12.2018
Verlag: BioMed Central
Erschienen in: Malaria Journal / Ausgabe 1/2018
Elektronische ISSN: 1475-2875
DOI: https://doi.org/10.1186/s12936-018-2181-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Background

Methods

Literature search

Statistical analysis

Results

Discussion

Conclusions

Authors’ contributions

Acknowledgements

Competing interests

Availability of data and materials

Consent for publication

Ethics approval and consent to participate

Funding

Publisher’s Note

Weitere Artikel der Ausgabe 1/2018

Factors associated with insecticide-treated net usage among women of childbearing age in Malawi: a multilevel analysis

Strain-transcending neutralization of malaria parasite by antibodies against Plasmodium falciparum enolase

Outreach training and supportive supervision for malaria case management in Zambia: the effects of focused capacity building on indicators of diagnostic and clinical performance

Optimal control of malaria: combining vector interventions and drug therapies

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy

Access and adequate utilization of malaria control interventions in rural Malawi: a descriptive quantitative study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

Update Innere Medizin